Examples of using An inducer in English and their translations into Polish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
Aprepitant is also an inducer of CYP2C9.
Bosentan is an inducer of the cytochrome P450(CYP) isoenzymes CYP2C9 and CYP3A4.
Therefore, laropiprant is not an inducer or inhibitor of CYP3A4.
Bosentan is an inducer of CYP2C9 and CYP3A4 and possibly also of CYP2C19 and the P-glycoprotein.
In this way,glucose represses the lac operon even if an inducer(lactose) is present.
People also translate
Rifampicin, which is an inducer of P-gp, reduced aliskiren bioavailability by approximately 50% in a clinical study.
Aprepitant is a substrate,a moderate inhibitor, and an inducer of CYP3A4.
Nevirapine has been shown to be an inducer of hepatic cytochrome P450 metabolic enzymes.
Aprepitant is a substrate, anda dose-dependent inhibitor, and an inducer of CYP3A4.
Rifampicin an inducer of all three cytochromes involved in the metabolism of agomelatine may decrease the bioavailability of agomelatine.
Aprepitant(125 mg/ 80 mg) is a substrate,a moderate inhibitor, and an inducer of CYP3A4.
Nevirapine is an inducer of CYP3A and potentially CYP2B6, with maximal induction occurring within 2-4 weeks of initiating multiple-dose therapy.
This indicates that sorafenib is neither an inhibitor nor an inducer of these cytochrome P450 isoenzymes.
Repeated doses of A771726 had no effect on the pharmacokinetics of S-warfarin,indicating that A771726 is not an inhibitor or an inducer of CYP2C9.
Rifampicin, a potent inducer of CYP3A4, but also CYP2C8, acts both as an inducer and inhibitor of the metabolism of repaglinide.
Dabrafenib is an inducer of metabolising enzymes which may lead to loss of efficacy of many commonly used medicinal products see examples in section 4.5.
According to Palatin Technologies' original 2003 patent for bremelanotide,it possesses approximately 50 times the potency of melanotan II as an inducer of erection in male rats.
Rifampicin(600 mg daily), a potent inducer of CYP3A and CYP2B6, and an inducer of CYP2C9, CYP2C19, and CYP2C8, did not significantly change the pharmacokinetics of prasugrel.
The lack of effect of cinacalcet on the pharmacokinetics of R- andS-warfarin and the absence of auto- induction upon multiple dosing in patients indicates that cinacalcet is not an inducer of CYP3A4, CYP1A2 or CYP2C9 in humans.
These results indicate that raltegravir is not an inducer or inhibitor of CYP3A4, and raltegravir is thus not anticipated to affect the pharmacokinetics of medicinal products which are CYP3A4 substrates.
However, the interaction study was of only 7 days duration andit cannot be excluded that vismodegib upon longer treatment is an inducer of enzymes which metabolise contraceptive steroids.
Efavirenz may be an inducer of CYP2C19 and CYP2C9; however, inhibition has also been observed in vitro and the net effect of co-administration with substrates of these enzymes is not clear see section 5.2.
The effect of enzalutamide on P-gp substrates has not been evaluated in vivo;however, under conditions of clinical use, enzalutamide may be an inducer of P-gp via activation of the nuclear pregnane receptor PXR.
In vitro, idelalisib was an inducer of several enzymes, and a risk for decreased exposure and thereby decreased efficacy of substrates of inducible enzymes such as CYP2C9, CYP2C19, CYP2B6 and UGT cannot be excluded.
Acetylsalicylic acid inhibits platelet aggregation by irreversible inhibition of prostaglandin cyclo-oxygenase andthus inhibits the generation of thromboxane A2, an inducer of platelet aggregation and vasoconstriction.
Following co-administration of canagliflozin with rifampicin(an inducer of various active transporters and drug-metabolising enzymes), 51% and 28% decreases in canagliflozin systemic exposure(AUC) and peak concentration(Cmax) were observed.
If an inducer of these UGT enzymes must be co-administered with canagliflozin, increasing the dose to 300 mg once daily may be considered if patients are currently tolerating canagliflozin 100 mg once daily, have an eGFR≥ 60 mL/min/1.73 m2 or CrCl≥ 60 mL/min, and require additional glycaemic control.
Concomitant administration of pioglitazone with gemfibrozil(an inhibitor of cytochrome P450 2C8)or with rifampicin(an inducer of cytochrome P450 2C8) is reported to increase or decrease, respectively, the serum concentration of pioglitazone see section 4.5.
If an inducer of these UGT enzymes must be co-administered with canagliflozin, increasing the dose to Vokanamet containing 150 mg twice daily may be considered if patients are currently tolerating canagliflozin 50 mg twice daily and require additional glycaemic control see sections 4.2 and 4.4.
